Introduction
This page provides a comprehensive analysis of the known insider trading history of John Pappajohn. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.
Average Trade Profitability
The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.
If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.
Update Frequency: Daily
Companies with Reported Insider Positions
The SEC filings indicate John Pappajohn has reported holdings or trades in the following companies:
Security | Title | Latest Reported Holdings |
---|---|---|
US:US87946W2026 / TELEMYND INC | Director, 10% Owner | 1,000,000 |
US:MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) | Director, 10% Owner | 1,117,925 |
US:US92942V2088 / VYANT BIO INC | Director | 4,781,204 |
US:HH / Hooper Holmes, Inc. | 10% Owner | 1,750,930 |
US:GNOW / American Caresource Holdings, Inc. | Director, 10% Owner | 6,278,672 |
US:KURA / Kura Oncology, Inc. | President, Director, 10% Owner | 0 |
US:CONM / Conmed Healthcare Management, Inc. | Director, 10% Owner | 0 |
US:PIP / PharmAthene, Inc. | Director | 10,000 |
How to Interpret the Charts
The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by John Pappajohn. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.
Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.
However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.
The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.
Insider Purchases ALT / Altimmune, Inc. - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALT / Altimmune, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
---|---|---|---|---|---|---|---|
There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales ALT / Altimmune, Inc. - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALT / Altimmune, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market sales that were not part of an automatic trading plan.
Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
---|---|---|---|---|---|---|---|
There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Purchases KURA / Kura Oncology, Inc. - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALT / Altimmune, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
---|---|---|---|---|---|---|---|
There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales KURA / Kura Oncology, Inc. - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALT / Altimmune, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market sales that were not part of an automatic trading plan.
Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
---|---|---|---|---|---|---|---|
There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Purchases MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALT / Altimmune, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales MYND / Mynd.ai, Inc. - Depositary Receipt (Common Stock) - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALT / Altimmune, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market sales that were not part of an automatic trading plan.
Trade Date | Ticker | Insider | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
---|---|---|---|---|---|---|---|
There are no known unplanned open-market trades for this insider and security combination |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Trading History
This table shows the complete list of insider trades made by John Pappajohn as disclosed to the Securities Exchange Commission (SEC).
File Date | Tran Date | Form | Ticker | Security | Code | Shares | Remaining Shares | Percent Change |
Share Price |
Tran Value |
Remaining Value |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-07-18 |
|
4 | NONE |
Telemynd, Inc.
Series A Preferred Stock |
J - Other | 1,000,000 | 1,000,000 | |||||
2019-07-18 |
|
4 | NONE |
Telemynd, Inc.
Common Stock |
J - Other | 1,132,925 | 1,132,925 | |||||
2019-05-23 |
|
4 | MYND |
MYnd Analytics, Inc.
COMMON STOCK |
P - Purchase | 200,000 | 1,117,925 | 21.79 | 1.25 | 250,800 | 1,401,878 | |
2019-03-14 |
|
4 | MYND |
MYnd Analytics, Inc.
COMMON STOCK |
P - Purchase | 100,000 | 917,925 | 12.23 | 1.68 | 167,600 | 1,538,442 | |
2019-02-01 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 1,000,000 | 4,781,204 | 26.45 | 0.23 | 230,000 | 1,099,677 | |
2019-01-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 1,000,000 | 3,781,204 | 35.96 | 0.22 | 225,000 | 850,771 | |
2018-10-10 |
|
4 | MYND |
MYnd Analytics, Inc.
COMMON STOCK |
A - Award | 30,000 | 832,925 | 3.74 | 1.38 | 41,400 | 1,149,436 | |
2018-09-25 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock Purchase Warrant |
A - Award | 135,135 | 135,135 | |||||
2018-09-25 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
A - Award | 135,135 | 802,925 | 20.24 | 1.85 | 250,000 | 1,485,411 | |
2018-08-28 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
A - Award | 50,000 | 667,790 | 8.09 | 1.63 | 81,500 | 1,088,498 | |
2018-08-28 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
A - Award | 50,000 | 617,790 | 8.81 | 1.62 | 81,000 | 1,000,820 | |
2018-08-28 |
|
4/A | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 50,000 | 667,790 | 8.09 | 1.63 | 81,500 | 1,088,498 | |
2018-08-28 |
|
4/A | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 50,000 | 617,790 | 8.81 | 1.62 | 81,000 | 1,000,820 | |
2018-05-30 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
A - Award | 4,500 | 567,790 | 0.80 | 2.27 | 10,215 | 1,288,883 | |
2018-04-02 |
|
4 | MYND |
MYnd Analytics, Inc.
Warrant |
A - Award | 500,000 | 500,000 | 62,500.00 | 31,250,000,000 | 31,250,000,000 | ||
2018-04-02 |
|
4 | MYND |
MYnd Analytics, Inc.
Warrant |
A - Award | 500,000 | 500,000 | 62,500.00 | 31,250,000,000 | 31,250,000,000 | ||
2018-04-02 |
|
4 | MYND |
MYnd Analytics, Inc.
Series A Preferred Stock |
A - Award | 500,000 | 500,000 | 937,500.00 | 468,750,000,000 | 468,750,000,000 | ||
2018-04-02 |
|
4 | MYND |
MYnd Analytics, Inc.
Series A Preferred Stock |
A - Award | 500,000 | 500,000 | 937,500.00 | 468,750,000,000 | 468,750,000,000 | ||
2018-01-08 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 10,000 | 563,290 | 1.81 | 3.44 | 34,378 | 1,936,478 | |
2017-12-11 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 150,000 | 2,781,204 | 5.70 | 1.86 | 279,000 | 5,173,039 | |
2017-10-02 |
|
4 | CGIX |
CANCER GENETICS, INC
Stock Option (right to buy) |
A - Award | 5,000 | 5,000 | |||||
2017-10-02 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
A - Award | 2,500 | 2,631,204 | 0.10 | ||||
2017-09-21 |
|
4 | MYND |
MYnd Analytics, Inc.
Director Stock Option (right to buy) |
A - Award | 12,000 | 12,000 | |||||
2017-09-21 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
A - Award | 12,000 | 553,290 | 2.22 | ||||
2017-08-18 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 20,000 | 2,628,704 | 0.77 | 3.28 | 65,560 | 8,616,892 | |
2017-08-18 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 66,185 | 2,608,704 | 2.60 | 3.24 | 214,108 | 8,439,157 | |
2017-08-18 |
|
4/A | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 20,000 | 2,628,704 | 0.77 | 3.28 | 65,560 | 8,616,892 | |
2017-08-18 |
|
4/A | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 66,185 | 2,608,704 | 2.60 | 3.24 | 214,108 | 8,439,157 | |
2017-08-10 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 541,290 | 0.93 | 3.34 | 16,684 | 1,806,122 | |
2017-08-03 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 536,290 | 0.94 | 3.65 | 18,242 | 1,956,600 | |
2017-07-26 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 531,290 | 0.95 | 4.00 | 19,996 | 2,124,735 | |
2017-07-25 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 526,290 | 0.96 | 4.20 | 20,993 | 2,209,681 | |
2017-07-25 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 521,290 | 0.97 | 4.30 | 21,500 | 2,241,547 | |
2017-07-19 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 516,290 | 0.98 | 4.54 | 22,694 | 2,343,389 | |
2017-07-19 |
|
4 | MYND |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 5,000 | 511,290 | 0.99 | 4.40 | 22,000 | 2,249,676 | |
2017-06-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 100,000 | 2,542,519 | 4.09 | 3.75 | 374,870 | 9,531,141 | |
2017-06-08 |
|
4 | CGIX |
CANCER GENETICS, INC
Stock Option (right to buy) |
A - Award | 10,000 | 10,000 | |||||
2017-06-08 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
A - Award | 2,500 | 2,442,519 | 0.10 | ||||
2017-05-17 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 19,310 | 2,440,019 | 0.80 | 3.80 | 73,318 | 9,264,508 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 59 | 1,750,930 | 0.00 | 0.85 | 50 | 1,488,290 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 474 | 1,750,871 | 0.03 | 0.85 | 403 | 1,488,240 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 12,125 | 1,750,397 | 0.70 | 0.85 | 10,306 | 1,487,837 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 3,186 | 1,738,272 | 0.18 | 0.75 | 2,388 | 1,302,661 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 4,300 | 1,735,086 | 0.25 | 0.75 | 3,225 | 1,301,314 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 20,077 | 1,730,786 | 1.17 | 0.75 | 15,050 | 1,297,397 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 1,400 | 1,710,709 | 0.08 | 0.75 | 1,047 | 1,278,926 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 700 | 1,709,309 | 0.04 | 0.75 | 525 | 1,281,982 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 336 | 1,708,609 | 0.02 | 0.75 | 252 | 1,281,457 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 15,852 | 1,708,273 | 0.94 | 0.74 | 11,795 | 1,271,126 | |
2017-04-21 |
|
4 | HH |
HOOPER HOLMES INC
Common Stock |
P - Purchase | 100,000 | 1,692,421 | 6.28 | 0.73 | 72,660 | 1,229,713 | |
2017-04-21 | 3 | HH |
HOOPER HOLMES INC
Common Stock |
3,184,842 | ||||||||
2017-04-21 | 3 | HH |
HOOPER HOLMES INC
Common Stock |
3,184,842 | ||||||||
2017-04-06 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 9,878 | 506,290 | 1.99 | 6.46 | 63,843 | 3,272,254 | |
2017-03-22 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
A - Award | 40,000 | 496,412 | 8.76 | 6.25 | 250,000 | 3,102,575 | |
2017-02-14 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
A - Award | 32,000 | 456,412 | 7.54 | 6.25 | 200,000 | 2,852,575 | |
2016-12-30 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
A - Award | 16,000 | 424,412 | 3.92 | 6.25 | 100,000 | 2,652,575 | |
2016-12-02 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
A - Award | 32,000 | 408,412 | 8.50 | 6.25 | 200,000 | 2,552,575 | |
2016-11-29 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 100,000 | 2,420,709 | 4.31 | 1.45 | 145,280 | 3,516,806 | |
2016-11-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 31,100 | 2,320,709 | 1.36 | 1.48 | 46,050 | 3,436,274 | |
2016-11-02 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
A - Award | 20,000 | 376,412 | 5.61 | ||||
2016-10-24 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 200 | 356,412 | 0.06 | 8.50 | 1,700 | 3,029,502 | |
2016-10-19 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 1,000 | 356,212 | 0.28 | 8.00 | 8,000 | 2,849,696 | |
2016-10-14 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 16 | 355,212 | 0.00 | 7.50 | 120 | 2,664,090 | |
2016-10-13 |
|
4 | CGIX |
CANCER GENETICS, INC
Stock Option (right to buy) |
A - Award | 10,000 | 10,000 | |||||
2016-10-13 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
A - Award | 2,500 | 2,289,609 | 0.11 | ||||
2016-10-12 |
|
4 | MYAN |
MYnd Analytics, Inc.
Common Stock |
P - Purchase | 1,839 | 355,196 | 0.52 | 6.45 | 11,867 | 2,291,973 | |
2016-09-23 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
D - Sale to Issuer | 0 | ||||||
2016-09-23 |
|
4 | CNSO |
MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017 |
M - Exercise | |||||||
2016-09-23 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock |
M - Exercise | 290,498 | 353,357 | 462.14 | 5.00 | 1,452,490 | 1,766,785 | |
2016-09-20 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock |
G - Gift | -6,538,258 | 12,571,699 | -34.21 | ||||
2016-08-17 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 45,000 | 2,287,109 | 2.01 | 2.29 | 103,203 | 5,245,256 | |
2016-08-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 79,722 | 2,242,109 | 3.69 | 2.20 | 175,636 | 4,939,590 | |
2016-08-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 67,778 | 2,162,387 | 3.24 | 2.10 | 142,652 | 4,551,176 | |
2016-08-11 |
|
4 | CNSO |
MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017 |
A - Award | 28,000,000 | ||||||
2016-08-11 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
A - Award | 2,000,000 | 28,000,000 | 7.69 | ||||
2016-07-25 |
|
4 | CNSO |
MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017 |
A - Award | 26,000,000 | ||||||
2016-07-25 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
A - Award | 5,000,000 | 26,000,000 | 23.81 | ||||
2016-07-19 |
|
4/A | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 317,820 | 2,094,609 | 17.89 | ||||
2016-07-05 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 46,112 | 6,278,672 | 0.74 | 0.20 | 9,222 | 1,255,734 | |
2016-06-30 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 13,800 | 6,232,560 | 0.22 | 0.20 | 2,760 | 1,246,512 | |
2016-06-29 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 26,453 | 6,245,213 | 0.43 | 0.20 | 5,291 | 1,249,043 | |
2016-06-29 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 5,000 | 6,218,760 | 0.08 | 0.20 | 1,000 | 1,243,752 | |
2016-06-27 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 26,500 | 6,213,760 | 0.43 | 0.20 | 5,300 | 1,242,752 | |
2016-06-27 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 27,000 | 6,187,260 | 0.44 | 0.20 | 5,400 | 1,237,452 | |
2016-06-23 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 11,909 | 6,160,260 | 0.19 | 0.19 | 2,256 | 1,166,753 | |
2016-06-23 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 20,600 | 6,148,351 | 0.34 | 0.18 | 3,708 | 1,106,703 | |
2016-06-21 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 5,383 | 6,127,751 | 0.09 | 0.20 | 1,077 | 1,225,550 | |
2016-06-14 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 29,148 | 6,122,368 | 0.48 | 0.20 | 5,830 | 1,224,474 | |
2016-06-13 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 53,000 | 6,093,220 | 0.88 | 0.20 | 10,600 | 1,218,644 | |
2016-06-08 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 4,500 | 6,040,220 | 0.07 | 0.20 | 900 | 1,208,044 | |
2016-06-01 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 32,363 | 6,035,720 | 0.54 | 0.20 | 6,473 | 1,207,144 | |
2016-05-31 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 15,000 | 6,003,357 | 0.25 | 0.20 | 3,000 | 1,200,671 | |
2016-05-27 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 72,211 | 5,988,357 | 1.22 | 0.20 | 14,442 | 1,197,671 | |
2016-05-26 |
|
4 | CGIX |
CANCER GENETICS, INC
Warrant (right to buy) |
P - Purchase | 158,910 | 158,910 | |||||
2016-05-26 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 317,820 | 2,099,609 | 17.84 | ||||
2016-05-26 |
|
4/A | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 2,500 | 1,524,289 | 0.16 | 10.25 | 25,624 | 15,623,353 | |
2016-05-26 |
|
4/A | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 2,500 | 1,521,789 | 0.16 | 8.97 | 22,436 | 13,657,143 | |
2016-05-25 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 25,008 | 5,916,146 | 0.42 | 0.20 | 5,002 | 1,183,229 | |
2016-05-24 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 71,878 | 5,891,138 | 1.24 | 0.20 | 14,376 | 1,178,228 | |
2016-05-23 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 59,000 | 5,819,260 | 1.02 | 0.20 | 11,800 | 1,163,852 | |
2016-05-20 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 100,000 | 5,760,260 | 1.77 | 0.17 | 17,420 | 1,003,437 | |
2016-04-13 |
|
4 | CNSO |
MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017 |
A - Award | 21,000,000 | ||||||
2016-04-13 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
A - Award | 5,000,000 | 21,000,000 | 31.25 | ||||
2016-04-07 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock |
A - Award | 250,000 | 19,109,957 | 1.33 | ||||
2016-04-04 |
|
4 | CNSO |
MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017 |
A - Award | 16,000,000 | ||||||
2016-04-04 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
A - Award | 5,000,000 | 16,000,000 | 45.45 | ||||
2016-04-04 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
A - Award | 493,500 | 5,660,260 | 9.55 | 0.41 | 199,966 | 2,293,537 | |
2016-03-17 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 50,000 | 1,771,789 | 2.90 | 2.64 | 132,060 | 4,679,649 | |
2016-03-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 10,579 | 1,721,789 | 0.62 | 2.62 | 27,734 | 4,513,842 | |
2016-03-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 89,421 | 1,711,210 | 5.51 | 2.52 | 225,144 | 4,308,485 | |
2015-12-28 |
|
4 | CNSO |
MYnd Analytics, Inc.
5% Secured Convertible Note due December 2017 |
A - Award | 11,000,000 | ||||||
2015-12-28 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
A - Award | 6,000,000 | 11,000,000 | 120.00 | ||||
2015-12-28 |
|
4 | CNSO |
MYnd Analytics, Inc.
Common Stock Warrant |
A - Award | 5,000,000 | 5,000,000 | |||||
2015-12-11 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Warrant to Purchase Common Stock |
A - Award | 2,857,142 | 2,857,142 | |||||
2015-12-11 |
|
4 | GNOW |
American CareSource Holdings, Inc.
Common Stock, par value $0.01 per share |
A - Award | 2,857,142 | 5,166,760 | 123.71 | ||||
2015-11-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Warrant (right to buy) |
P - Purchase | 100,000 | 100,000 | |||||
2015-11-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 100,000 | 1,621,789 | 6.57 | ||||
2015-10-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Stock Option (right to buy) |
A - Award | 10,000 | 10,000 | |||||
2015-10-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
A - Award | 2,500 | 1,521,789 | 0.16 | ||||
2015-09-16 |
|
4 | CNSO |
CNS RESPONSE, INC.
5% Secured Convertible Note due March 2016 |
A - Award | |||||||
2015-09-16 |
|
4 | CNSO |
CNS RESPONSE, INC.
5% Secured Convertible Note due March 2016 |
A - Award | |||||||
2015-09-04 |
|
4 | ANCI |
American CareSource Holdings, Inc.
Warrant to Purchase Common Stock, par value $0.01 per share |
A - Award | 150,000 | 150,000 | |||||
2015-09-01 |
|
4 | ANCI |
American CareSource Holdings, Inc.
Common Stock |
A - Award | 10,000 | 2,289,398 | 0.44 | ||||
2015-08-27 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 2,500 | 1,519,289 | 0.16 | 10.25 | 25,624 | 15,572,105 | |
2015-08-27 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 2,500 | 1,516,789 | 0.17 | 8.97 | 22,436 | 13,612,271 | |
2015-08-24 |
|
4 | CNSO |
CNS RESPONSE, INC.
Option to Purchase |
A - Award | 250,000 | 250,000 | |||||
2015-05-18 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 5,000 | 1,519,289 | 0.33 | 10.74 | 53,700 | 16,317,164 | |
2015-04-27 |
|
4 | ANCI |
American CareSource Holdings, Inc.
Stock option (right to buy) |
M - Exercise | -18,744 | 0 | -100.00 | ||||
2015-04-27 |
|
4 | ANCI |
American CareSource Holdings, Inc.
Common Stock |
M - Exercise | 18,744 | 2,279,398 | 0.83 | 0.93 | 17,488 | 2,126,678 | |
2015-03-18 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 15,000 | 1,514,289 | 1.00 | 7.15 | 107,236 | 10,825,803 | |
2015-03-18 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 35,000 | 1,499,289 | 2.39 | 7.45 | 260,586 | 11,162,656 | |
2015-03-10 |
|
4 | NONE |
ZETA ACQUISITION CORP III
Common Stock, par value $0.0001 per share |
D - Sale to Issuer | -2,000,000 | 0 | -100.00 | ||||
2014-12-17 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 5,589 | 1,464,289 | 0.38 | 6.20 | 34,652 | 9,078,592 | |
2014-12-16 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 3,634 | 1,458,700 | 0.25 | 6.14 | 22,313 | 8,956,418 | |
2014-12-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 27,087 | 1,455,066 | 1.90 | 6.03 | 163,335 | 8,774,048 | |
2014-12-11 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 5,773 | 1,427,979 | 0.41 | 5.96 | 34,407 | 8,510,755 | |
2014-12-10 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 15,986 | 1,422,206 | 1.14 | 5.70 | 91,120 | 8,106,574 | |
2014-12-10 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 23,700 | 1,406,220 | 1.71 | 5.11 | 121,107 | 7,185,784 | |
2014-12-08 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Warrant to Purchase Common Stock |
A - Award | 480,000 | 480,000 | |||||
2014-08-01 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Warrant to Purchase Common Stock |
A - Award | 440,000 | 440,000 | |||||
2014-06-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Warrant (right to buy) |
M - Exercise | 44,288 | 0 | -100.00 | ||||
2014-06-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
M - Exercise | 44,288 | 1,382,520 | 3.31 | 4.00 | 177,152 | 5,530,080 | |
2014-06-05 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Common Stock, $0.01 par value per share |
A - Award | 10,000 | 2,302,665 | 0.44 | ||||
2014-05-27 |
|
4 | CGIX |
CANCER GENETICS, INC
Stock Option (right to buy) |
A - Award | 100,000 | 100,000 | |||||
2014-05-27 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
A - Award | 25,000 | 1,338,232 | 1.90 | ||||
2014-05-21 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 5,000 | 1,313,232 | 0.38 | 10.66 | 53,300 | 13,999,053 | |
2014-05-21 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 30,000 | 1,308,232 | 2.35 | 10.35 | 310,500 | 13,540,201 | |
2014-05-21 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 15,000 | 1,278,232 | 1.19 | 10.10 | 151,500 | 12,910,143 | |
2014-05-07 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Common Stock, $0.01 par value per share |
P - Purchase | 575,000 | 2,292,665 | 33.48 | 2.00 | 1,150,000 | 4,585,330 | |
2013-10-15 |
|
4 | CGIX |
CANCER GENETICS, INC
Stock Option (right to buy) |
A - Award | 10,000 | 10,000 | |||||
2013-09-20 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Common Stock, $0.01 par value per share |
P - Purchase | 3,400 | 1,717,665 | 0.20 | 1.82 | 6,188 | 3,126,150 | |
2013-09-20 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Common Stock, $0.01 par value per share |
P - Purchase | 1,300 | 1,714,265 | 0.08 | 1.70 | 2,210 | 2,914,250 | |
2013-09-20 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Common Stock, $0.01 par value per share |
P - Purchase | 100 | 1,712,965 | 0.01 | 1.73 | 173 | 2,963,429 | |
2013-08-30 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock |
A - Award | 400,000 | 18,859,957 | 2.17 | 0.25 | 100,000 | 4,714,989 | |
2013-08-14 |
|
4 | CNSO |
CNS RESPONSE, INC.
Convertible Note |
M - Exercise | 0 | ||||||
2013-08-14 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock |
M - Exercise | 7,318,228 | 18,459,957 | 65.68 | 0.25 | 1,829,557 | 4,614,989 | |
2013-06-06 |
|
4 | CNSO |
CNS RESPONSE, INC.
Convertible Note |
M - Exercise | 0 | ||||||
2013-06-06 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock |
M - Exercise | 6,538,258 | 11,141,729 | 142.03 | 0.05 | 308,606 | 525,890 | |
2013-06-06 |
|
4 | CNSO |
CNS RESPONSE, INC.
Convertible Note |
M - Exercise | |||||||
2013-06-06 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock |
M - Exercise | 4,300,551 | 4,603,471 | 1,419.70 | 0.05 | 202,986 | 217,284 | |
2013-06-04 |
|
4 | ANCI |
American Caresource Holdings, Inc.
Common Stock |
A - Award | 10,000 | 1,722,865 | 0.58 | ||||
2013-05-28 |
|
4 | CNSO |
CNS RESPONSE, INC.
Option to Purchase |
A - Award | 250,000 | 250,000 | |||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Convertible Note |
C - Conversion | 0 | ||||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Series A-1 Convertible Preferred Stock |
C - Conversion | -377,789 | 0 | -100.00 | ||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Convertible Note |
C - Conversion | 0 | ||||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Convertible Note |
C - Conversion | 0 | ||||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Convertible Note |
C - Conversion | 0 | ||||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
C - Conversion | 80,686 | 1,263,232 | 6.82 | ||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 200,000 | 1,182,546 | 20.36 | ||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 200,000 | 1,182,546 | 20.36 | ||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 100,000 | 782,546 | 14.65 | ||||
2013-04-12 |
|
4 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
P - Purchase | 175,000 | 682,546 | 34.48 | ||||
2013-04-04 | 3 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
307,546 | ||||||||
2013-04-04 | 3 | CGIX |
CANCER GENETICS, INC
Common Stock, par value $0.0001 per share |
200,000 | ||||||||
2012-12-13 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
D - Sale to Issuer | 83,334 | 0 | -100.00 | ||||
2012-12-13 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
D - Sale to Issuer | 83,334 | 0 | -100.00 | ||||
2012-12-13 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
D - Sale to Issuer | 83,334 | 0 | -100.00 | ||||
2012-12-13 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
D - Sale to Issuer | 126,949 | 0 | -100.00 | ||||
2012-12-13 |
|
4 | CNSO |
CNS RESPONSE, INC.
Convertible Promissory Notes |
A - Award | |||||||
2012-08-30 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Employee Stock Option (right to buy) |
D - Sale to Issuer | -40,000 | 0 | -100.00 | 1.40 | -56,000 | ||
2012-08-30 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Common Stock |
D - Sale to Issuer | -5,496 | 0 | -100.00 | 3.95 | -21,709 | ||
2012-08-30 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Common Stock |
D - Sale to Issuer | -5,000 | 0 | -100.00 | 3.95 | -19,750 | ||
2012-08-30 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Common Stock |
D - Sale to Issuer | -1,539,012 | 0 | -100.00 | 3.95 | -6,079,097 | ||
2012-07-18 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Common Stock |
G - Gift | -1,000,000 | 1,539,012 | -39.39 | ||||
2012-05-29 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Common Stock |
M - Exercise | 10,000 | 2,539,012 | 0.40 | ||||
2012-02-22 |
|
4 | CONM |
Conmed Healthcare Management, Inc.
Restricted Stock Units |
A - Award | 10,000 | 10,000 | |||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
A - Award | 2,500,000 | 7,500,000 | 50.00 | ||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Subordinated Convertible Note |
A - Award | 250,000 | 750,000 | 50.00 | ||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
A - Award | 2,500,000 | 5,000,000 | 100.00 | ||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Subordinated Convertible Note |
A - Award | 250,000 | 500,000 | 100.00 | ||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
A - Award | 1,250,000 | 2,500,000 | 100.00 | ||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Common Stock Warrant |
A - Award | 1,250,000 | 1,250,000 | |||||
2012-01-05 |
|
4 | CNSO |
CNS RESPONSE, INC.
Subordinated Convertible Note |
A - Award | 250,000 | 250,000 | |||||
2009-03-11 |
|
4 | PIP |
PHARMATHENE, INC
Stock option (right to buy) |
A - Award | 10,000 | 10,000 |